Researchers at the University of California, San Diego
Moores Cancer Center have identified a humanized monoclonal antibody that
targets and directly kills chronic lymphocytic leukemia (CLL) cells.
The findings, published in the online Early Edition of the
Proceedings of the National Academy of Sciences on March 25, 2013 represent a
potential new therapy for treating at least some patients with CLL, the most
common type of blood cancer in the United States.